Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-6450 · 2 trials · 2 indications
Number, type, severity, and association of treatment emergent adverse events.
| Arm | Type | Description |
|---|---|---|
| TD-6450 | EXPERIMENTAL | TD-6450 capsules |
| Placebo | PLACEBO_COMPARATOR | Placebo capsules |
| SAD TD-6450 | PLACEBO_COMPARATOR | Single ascending dose (Part A) |
| MAD TD-6450 | PLACEBO_COMPARATOR | Multiple ascending dose (Part B) |
| Food effect of TD-6450 | ACTIVE_COMPARATOR | Food effect will be assessed in Part A (SAD) of this study. |
| Name | Type | Description |
|---|---|---|
| TD-6450 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Subject is HCV antibody positive * Subject is treatment naïve, with no history of exposure (single or multiple dose) to interferon, ribavirin or direct acting antivirals. * Subject has had a liver biopsy within 3 years or Fibroscan evaluation within 6 months prior to Screening...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
TD-6450 is an investigational small molecule being developed for the treatment of Hepatitis C. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in both healthy subjects and patients with Hepatitis C infection.
TD-6450 is being developed by Theravance Biopharma, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol TBPH. The drug is currently in Phase 1 clinical development for the treatment of Hepatitis C.
TD-6450 is in Phase 1 clinical development. It is an investigational drug for the treatment of Hepatitis C and has not yet been approved by regulatory authorities. The drug is still in early-stage clinical trials to evaluate its safety and tolerability.
TD-6450 has completed two Phase 1 clinical trials. The first trial, NCT02022306, was a single and multiple ascending dose study in healthy subjects with 111 participants. The second trial, NCT02116543, was a multiple ascending dose study in 47 patients with Hepatitis C. Both trials were conducted in the United States.
TD-6450 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of Hepatitis C. The drug has completed two Phase 1 trials, but it has not yet received regulatory approval and remains under clinical investigation.